Market closed
Spruce Biosciences/$SPRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Ticker
$SPRB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
22
Website
SPRB Metrics
BasicAdvanced
$13M
-
-$0.96
2.37
-
Price and volume
Market cap
$13M
Beta
2.37
52-week high
$0.87
52-week low
$0.26
Average daily volume
252K
Financial strength
Current ratio
5.361
Quick ratio
5.065
Long term debt to equity
2.581
Total debt to equity
6.255
Interest coverage (TTM)
-121.12%
Management effectiveness
Return on assets (TTM)
-30.35%
Return on equity (TTM)
-57.55%
Valuation
Price to revenue (TTM)
1.819
Price to book
0.25
Price to tangible book (TTM)
0.25
Price to free cash flow (TTM)
-0.278
Growth
Revenue change (TTM)
-1.40%
Earnings per share change (TTM)
-33.17%
3-year earnings per share growth (CAGR)
-19.05%
What the Analysts think about SPRB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Spruce Biosciences stock.
SPRB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SPRB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SPRB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Spruce Biosciences stock?
Spruce Biosciences (SPRB) has a market cap of $13M as of April 16, 2025.
What is the P/E ratio for Spruce Biosciences stock?
The price to earnings (P/E) ratio for Spruce Biosciences (SPRB) stock is 0 as of April 16, 2025.
Does Spruce Biosciences stock pay dividends?
No, Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Spruce Biosciences dividend payment date?
Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Spruce Biosciences?
Spruce Biosciences (SPRB) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.